Arachidonic acid triggers \([\text{Ca}^{2+}]_i\) increases in rat round spermatids by a likely GPR activation, ERK signalling and ER/acidic compartments \(\text{Ca}^{2+}\) release

Joaquin Paillamanque\(^1\), Ana Sanchez-Tusie\(^2\), Emerson M. Carmona\(^1\), Claudia L. Treviño\(^2\), Carolina Sandoval\(^1\), Francisco Nualart\(^3\), Nelson Osses\(^1\), Juan G. Reyes\(^1\)*

\(^1\) Instituto de Química, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile, \(^2\) Departamento de Genética del Desarrollo y Fisiología Molecular, Instituto de Biotecnología, Universidad Autónoma de México, Cuernavaca, México, \(^3\) Departamento de Biología Celular, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile

* juan.reyes@pucv.cl

Abstract

Arachidonic acid (AA), a compound secreted by Sertoli cells (SC) in a FSH-dependent manner, is able to induce the release of \(\text{Ca}^{2+}\) from internal stores in round spermatids and pachytene spermatocytes. In this study, the possible site(s) of action of AA in round spermatids, the signalling pathways associated and the intracellular \(\text{Ca}^{2+}\) stores targeted by AA-induced signalling were pharmacologically characterized by measuring intracellular \(\text{Ca}^{2+}\) using fluorescent \(\text{Ca}^{2+}\) probes. Our results suggest that AA acts by interacting with a fatty acid G protein coupled receptor, initiating a G protein signalling cascade that may involve PLA2 and ERK activation, which in turn opens intracellular ryanodine-sensitive channels as well as NAADP-sensitive channels in acidic intracellular \(\text{Ca}^{2+}\) stores. The results presented here also suggest that AMPK and PKA modulate this AA-induced \(\text{Ca}^{2+}\) release from intracellular \(\text{Ca}^{2+}\) stores in round spermatids. We propose that unsaturated free fatty acid lipid signalling in the seminiferous tubule is a novel regulatory component of rat spermatogenesis.

Introduction

The functional relationship between germ and Sertoli cells (SCs) in the mammalian seminiferous tubules takes place through adhesion molecules and molecules secreted to the extracellular space in the adluminal compartment [1–3]. The precise composition of the extracellular environment of germinal cells in the seminiferous tubules remains unknown, but it is well established that SCs secrete molecules that are crucial for the spermatogenic process to proceed. Among several molecules, SCs release arachidonic acid (AA) and some of its metabolites in a FSH-regulated manner [4]. In a SC-derived cell line (TM4) the activation of CD95 (Fas), a pathway that participates in spermatogenic cell apoptosis [5,6] can activate cytosolic PLA2 and AA release [7]. Furthermore, AA has been shown to be able to activate glycolytic lactate...
production in SCs in an autocrine loop [8]. These evidences strongly suggest that AA is part of the cell-cell signalling regulatory network of spermatogenesis; a role that is also emphasized by the large effect that AA has as a nutrient on animal fertility [9], and by the infertility effects seen after knocking-down a group VI PLA2 isoform expressed in mice testes [10].

In a previous work, we showed that AA and other unsaturated fatty acids (UFA) were able to release \( \text{Ca}^{2+} \) from intracellular \( \text{Ca}^{2+} \) stores (ICaS) in a dose-dependent manner in pachytene spermatocytes and round spermatids [11]. In this work, we provide evidence that agonists for GPR120 but not for GPR40 (both GPRs activated by medium and long chain FAs) were able to induce an increase in intracellular \( \text{Ca}^{2+} \) concentration (\([\text{Ca}^{2+}]_i\)) in spermatogenic cells in the nominal absence of external \( \text{Ca}^{2+} \). This \( \text{Ca}^{2+} \) was released from ICaS, similarly to the effects of AA. Immunohistochemistry showed that GPR120 was present in spermatogenic cells. Using pharmacological effectors of downstream signalling pathways in these cells, we determined that the AA effect of releasing \( \text{Ca}^{2+} \) from ICaS was sensitive to ERK and PLA2 inhibition. Furthermore, modulators of AMPK and PKA affect this AA-induced intracellular \( \text{Ca}^{2+} \) release in round spermatids. Both the cADPribose-sensitive channel inhibitor ryanodine and the NAADP-sensitive channel inhibitor NED19 were able to slow the release of \( \text{Ca}^{2+} \) elicited by AA. We also showed that round spermatids presented NAADP-sensitive ICaS, which is consistent with the inhibitory action of NED19 on AA-induced \( \text{Ca}^{2+} \) release from ICaS. Thus, we provide evidences to support the hypothesis that UFAs can be part of the cell-cell signalling mechanisms in seminiferous tubules, leading to the control of spermatogenic cell differentiation or death by SCs in the testes.

Materials and methods

Animals

Adult (40–60 days old) male Sprague–Dawley rats were acquired from the Animal Facility in the Faculty of Sciences University of Valparaiso. The rats were housed under a 12L:12D cycle with water and rat chow \textit{ad libitum}. Adult rats were maintained in groups of four animals per cage. Two rats were chosen at random and their testicles were used to isolate round spermatids as described below.

Ethical statement

All the experiments were conducted in accordance with the guidelines outlined by the Consortium for Development in the Guide for the Care and Use of Agricultural Animals in Agricultural Research and Teaching and by the National Research Council. All experimental protocols were reviewed and approved by the Chilean National Fund for Science and Technology (FONDECYT) and the Ethics Committee of the Pontificia Universidad Católica de Valparaíso (EC-PUCV-10/2013). None of the authors served on this committee.

Rat pachytene spermatocytes and round spermatid isolation

The testicles were obtained from adult (60 day old) male Sprague–Dawley rats. The rats were exposed to \( \text{CO}_2 \) and then killed by cervical dislocation. Rat spermatogenic cell populations were isolated using velocity sedimentation separation in a 2–4\% BSA gradient, as described by Romrell \textit{et al.} (1976) [12]. The round spermatid fraction (92±4\% purity) was identified both by its size as well as by its typical nuclear aspect after staining with Hoescht 33342 [13].
Reagents

Fura-2 acetoxy methyl ester, 2',7'-Bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxy methyl ester (BCECF) and Hoescht 33342 were purchased from Molecular Probes (Life Technologies, USA). Ryanodine, GPR40 agonist (PPMAPP, 3-(4-((3-(Phenoxy)phenyl)methyl)(amino)phenyl)propanoic acid), ERK Activation Inhibitor Peptide I, ERK Activation Inhibitor Peptide II (5-(2-Phenyl-pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridazin-3-ylamine), GPR120 agonist III (3-(4-((4-Fluoro-4'-methyl-(1,1'-biphenyl)-2-yl)ethoxy)-phenyl)propanoic acid), GPR40 agonist II (3-(4-((2,6-Dichloropyridin-4-yl)ethynyl)phenyl)propanoic acid), okadaic acid (OA, 9,10-Deepthio-9,10-didehydroacanthifolin, cantharidin (Canth, (3α,4β,7β,7αα)-Hexahydro-3α,7α-dimethyl-4,7-epoxyisobenzofuran-1,3-dione), cyclosporin A and RU360 were purchased from Calbiochem (Merck Chem. Co., Chile). Arachidonic acid, dantrolene, caffeine, 2-APB (2-aminoethyl diphenyl borate), enzymes, salts and buffers were obtained from Sigma-Aldrich (St. Louis, MO, USA). Grifolic acid (2,4-Dihydroxy-6-methyl-3-[(E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl]-benzoic acid), PT1 (2-Chloro-5-[[5-[(4,5-Dimethyl-2-nitrophenyl)-2-furanyl]methylene]-4,5-dihydro-4-oxo-2-thiazoyl]amino]benzoic acid), H89 (N-[2-[[3-(4-Bromophenyl)-2-propenyl][amino][ethyl]-5-isouquinolinesulfonamide dihydrochloride) and transNED19 ((1R,3S)-1-[3-[[4-(2-Fluorophenyl)piperazin-1-yl]methyl]-4-methoxyphenyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid) were obtained from Tocris Bioscience (R&D Systems, Gene X-Press, Chile). All the agonists, activators or inhibitors used in this work are listed in Table 1 together with their main target and effect, as well as their source and representative references.

Intracellular Ca$^{2+}$ measurements of rat spermatogenic cells

Cells in suspension (20 x 10$^6$ cells/mL) were loaded with 5 μM Fura-2 AM by incubation for 1 h at room temperature under an O$_2$ atmosphere. Thereafter, the cells were washed three times in KH-lactate medium (in mM, NaCl: 140; KCl: 4; MgCl$_2$:1.6; CaCl$_2$: 0.5; KH$_2$PO$_4$: 1.6; HEPES 10; DL lactate: 10; pH 7.4; pH balanced with NaOH) and maintained in this media unless stated otherwise. The measurements were performed by adding concentrated cells in suspension (50 μl, to reach 2x10$^6$ cells/ml) to a temperature-regulated and stirred spectro-fluorimeter cuvette that contained 2.5 mL of a KH-no Ca$^{2+}$-EGTA-lactate (0.5 mM EGTA, 10 mM DL lactate) solution in a Fluoromax 2 fluorimeter (Jobin-Yvon-Spex, NJ, USA). [Ca$^{2+}$]i was calculated using a ratiometric method as described by [53]. Fura-2 calibration was performed by cell lysis with digitonin (20 μg/mL) and addition of EGTA to 1.5 mM final concentration (Fmin). Fmax was obtained by addition of a CaCl$_2$ solution to the digitonin-treated cell suspension giving 3 mM final Ca$^{2+}$ concentration. The N reported is the number of measurements performed in at least three cell preparations with four testicles each. The results are expressed as the mean ± standard error of the mean (SEM).

Immune histochemistry

The testes of 60 day old Sprague-Dawley rats were removed and submerged immediately for 4 h in Bouin’s solution or modified Davidson solution [54] for immunohistochemistry or immunofluorescence, respectively. Subsequently, holes were punctured in the tunica albuginea using a needle and the testes submerged again in the fixative fluid for 20 h. They were then washed in PBS for 30 min and cryoprotected with 10%, 20% and 30% (w/v) sucrose in PBS for 4 h, 4 h and overnight, respectively. Testes sections of 12 μm were cut using a microtome cryostat (HM 525, MICROM International GmbH) at -20°C and stored at the same
temperature until use. Immunohistochemistry was performed using a Lab Vision™ UltraVision™ Detection System: anti-Rabbit HRP/DAB (Thermo Scientific, TR-015-HD) according to the manufacturer instructions. Briefly, sections were thawed at room temperature and rehydrated in PBS. Endogenous peroxidase activity was quenched with 10% H₂O₂ solution.

Table 1. Pharmacological effectors.

| Name                  | Target and Effect                                      | Source                   | References  |
|-----------------------|--------------------------------------------------------|--------------------------|-------------|
| GPR120 agonist III    | GPR120 agonist                                         | Calbiochem               | [14]        |
| GPR40 agonist II      | GPR40 agonist                                          | Calbiochem               | [15]        |
| Grifolic acid         | GPR120 agonist                                         | Tocris Bioscience        | [16]        |
| PPMAPP                | GPR40 agonist                                          | Calbiochem               | [17]        |
| Mastoparan X          | G protein analogue; Membrane permeant                  | Tocris Bioscience        | [18–20]     |
| SCH202676             | GPR/G protein binding inhibitor (sulfhydryl reagent); Membrane permeant | Tocris Bioscience        | [21,22]     |
| SP 4–11               | Substance P-peptide inhibitor of G protein binding to GPR; Membrane permeant | Tocris Bioscience        | [23,24]     |
| Akt Inhibitor 4       | Akt inhibitor; Membrane permeant                       | Calbiochem               | [25]        |
| Akt Inhibitor 5       | Akt inhibitor; Membrane permeant                       | Calbiochem               | [25]        |
| ERK inhibitory peptide I | ERK inhibitor; Membrane permeant                     | Calbiochem               | [26]        |
| ERK inhibitory peptide II | ERK inhibitor; Membrane permeant                     | Calbiochem               | [26]        |
| Wortmannin            | PI3K inhibitor; Membrane permeant                      | Calbiochem               | [27]        |
| Bisindolylmaleimide   | PKC inhibitor; Membrane permeant                       | Sigma-Aldrich            | [29]        |
| Calmidazolium         | CaM inhibitor; Membrane permeant                       | Calbiochem               | [29]        |
| Forskolin             | Adenyl cyclase activator; Membrane permeant            | Calbiochem               | [30]        |
| H89                   | PKA inhibitor (see Lochner and Moolman, 2006 for other targets); Membrane permeant | Tocris Bioscience        | [31,32]     |
| KN-62                 | CaMK inhibitor; Membrane permeant                      | Calbiochem               | [33]        |
| PT1                   | AMPK activator; Membrane permeant                      | Tocris Bioscience        | [34,35]     |
| Trifluoperazine       | CaM inhibitor; Membrane permeant                       | Sigma-Aldrich            | [36]        |
| Cantharidin           | Proteinase 1 and 2A inhibitor; Membrane permeant       | Calbiochem               | [37]        |
| Cyclosporine A        | Calcineurin inhibitor; Membrane permeant               | Calbiochem               | [38]        |
| Okadaic acid          | Proteinase 1 and 2A inhibitor; Membrane permeant       | Calbiochem               | [39]        |
| Aristolochic acid     | PLA2 inhibitor, Membrane permeant                      | Sigma-Aldrich            | [40,41]     |
| U73122                | PLC inhibitor; Membrane permeant                       | Sigma                    | [42,43]     |
| U73343                | Inactive Analogue of U73122; Membrane permeant         | Sigma                    | [43]        |
| Caffeine              | RyR sensitizer, cAMP phosphodiesterase inhibitor; Membrane permeant | Sigma-Aldrich            | [44]        |
| Danzatrolene          | cADPribos-sensitive channel inhibitor (RyR); Membrane permeant | Sigma-Aldrich            | [45]        |
| transNED19            | NAADP-sensitive channel inhibitor; Membrane permeant   | Tocris Bioscience        | [46]        |
| RU360                 | Mitochondrial Ca²⁺ uptake inhibitor; Membrane Permeant | Calbiochem               | [47]        |
| 2-APB                  | IP3-sensitive channel inhibitor; Membrane permeant     | Sigma-Aldrich            | [48]        |
| Ryanodine             | cADPribos-sensitive channel inhibitor (RyR); Membrane permeant | Calbiochem, Tocris Bioscience | [49–51]     |
| NAADP-AM              | Two pore channel agonist; Membrane permeant            | Synthesized              | [52]        |

Each bracketed number represents a Figure number: (1) GPCR’s agonists; (3) G Protein/GPR effectors; (S3A) MAPK-Akt; (S3B) CaM-PKC-PKA-CaMK-AMPK; (S3C) PL inhibitors; (S3D) Protein phosphatases effectors; (5, 6) ICaS Ca²⁺ transport effectors.

doi:10.1371/journal.pone.0172128.t001
then incubated with anti-GPR120 antibody (H-155: sc-99105, rabbit polyclonal; raised against amino acids 78–232 at the C-terminus of human GPR120, Santa Cruz Biotechnology) at 4 µg/mL in a humid chamber at 4˚C overnight, washed, and incubated with biotinylated goat anti-rabbit antibody (1:300). After washing, the sections were incubated with streptavidin-peroxidase, washed, and a mixture of DAB chromogen and substrate was added until a brown colour was visible and the reaction was stopped with water. Sections were counterstained using hematoxylin, dehydrated with alcohol solutions and xylol, and mounted using Entellan. Microscopic observations and picture acquisitions were performed using a Nikon Diaphot Microscopy and Nikon D3000 Camera. Adjustments of brightness and contrast in the images were made using ImageJ software [55].

To perform immunofluorescence staining, thawed slides were washed with a buffer containing 3.5 mM KH$_2$PO$_4$, 120 mM NaCl, 10 mM Tris, and 8.4 mM Na$_2$HPO$_4$, pH 7.8 (Tris-P buffer) and subjected to an antigen retrieval protocol in 10 mM citrate buffer pH 6.0 heated for 5 minutes in a microwave. Slides were left 30 minutes at room temperature in the heated antigen retrieval buffer and then washed with Tris-P buffer. Anti-GPR120 antibody (H-155: sc-99105, rabbit polyclonal; raised against amino acids 78–232 at the C-terminus of human GPR120, Santa Cruz Biotechnology) at 8 µg/mL and anti-Proliferating Cell Nuclear Antigen antibody (anti-PCNA, M0879, mouse monoclonal, Dako) at 1:300 dilution were mixed in Tris-P buffer 1% BSA. Slides were incubated in this primary antibody mixture in a humid chamber at room temperature overnight, then washed, and incubated with a secondary antibody mixture containing anti-rabbit IgG antibody conjugated to Alexa Fluor 488 (711-545-152, donkey polyclonal, Jackson ImmunoResearch) and anti-mouse IgG antibody conjugated to DyLight 549 (715-505-150, donkey polyclonal, Jackson ImmunoResearch), both at 1:200 dilution, and Hoechst 33258 at 2 µg/mL in Tris-P buffer 1% BSA. Incubation was performed in a humid chamber at room temperature, and protected from light for 2 hours, and then slides were washed with Tris-P buffer, and mounted. Spectral confocal microscope (Zeiss 780) was used to obtain images.

**Synthesis of acetoxymethyl NAADP**

NAADP and NAADP-AM were synthesized from NADP as previously described [56].

**Data and statistical analysis**

The initial rate of effector-induced Ca$^{2+}$ entry was estimated by linear regression of the [Ca$^{2+}$]$_i$ vs time, recorded between 30 and 200 s after addition of the compounds. Statistical differences between treatment and control rates of [Ca$^{2+}$]$_i$, changes were analyzed by applying ANOVA followed by Welch’s t test. When the data was expressed as the percentage increase in [Ca$^{2+}$]$_i$ by AA in the absence or presence of different effectors of [Ca$^{2+}$]$_i$, homeostatic mechanisms or signalling pathways, or when the F test indicated significant differences in group variances, the comparison between treatment and control was performed using non-parametrical Mann-Whitney analysis.

**Results**

**GPR120 agonists and AA increased [Ca$^{2+}$]$_i$ in spermatogenic cells**

Fig 1 shows the dose response curves for the [Ca$^{2+}$]$_i$ increase caused by the addition of arachidonic acid (AA), grifolic acid (GA, GPR120 agonist), GPR120 agonist 3, PPMAPP (GPR40 agonist) and GPR40 agonist 2 in round spermatids incubated in KH lactate-EGTA media (see
also [11]). Fitting of hyperbolic dose-response curves gave \( K_{0.5} \) and \( V_{\text{max}} \) values of 4.6±1.0 μM and 4.3±0.4 nM/s; and 4.2±1.0 μM and 0.8±0.1 nM/s for grifolic acid and AA, respectively. Thus, although it had a similar \( K_{0.5} \) to AA, grifolic acid was able to induce approximately a five times faster release of Ca\(^{2+}\) from ICaS than AA at saturating concentrations. GPR120 agonist 3 at 5 and 10 μM, although not reaching saturation, was able to induce Ca\(^{2+}\) release from ICaS at higher rates compared to GPR40 agonists, but at lower rates compared to GA or AA at similar concentrations. Except at 10 and 50 nM, PPMAPP did not induce a significant increase in [Ca\(^{2+}\)]\( _i \) even at 10 μM. GPR40 agonist 2 did not increase significantly the [Ca\(^{2+}\)]\( _i \) in round spermatids. These data strongly suggest that AA may be acting through a similar mechanism to the GPR120 agonists, e.g., by activating a G protein-coupled receptor.

The kinetics of grifolic acid-induced intracellular Ca\(^{2+}\) release in round spermatids is shown in S1 Fig. The effect of 4 μM AA acid on [Ca\(^{2+}\)]\( _i \) was diminished as the GA concentration increased, and at 10 μM GA, it was completely abolished. These results strongly suggest that GA and AA release Ca\(^{2+}\) from similar ICaS in round spermatids.

**Expression and distribution of GPR120 in rat testes**

To explore the presence of GPR120 in round spermatids as suggested by the pharmacological data and the AA-induced [Ca\(^{2+}\)]\( _i \) increase, we utilized an antiGPR120 antibody to perform immunohistochemistry in rat testes. **Fig 2A and 2B** shows that the antiGPR120 antibody gives a stronger staining toward the luminal side of the seminiferous tubules. Confocal images in **Fig 2C and 2D** corroborate that GPR120 appears strongly on interstitial cells and also on spermatogenic cells close to the lumen of the tubules. The anti-PCNA antibody shows a well-defined staining on basal cells, presumably, dividing spermatogonia. However, these images cannot discard that part of the GPR120 labelling could be present also on Sertoli cell projections.
Basal effects of the pharmacological agents on [Ca\textsuperscript{2+}]\textsubscript{i} in round spermatids

In the conditions used in our measurements, round spermatids [Ca\textsuperscript{2+}]\textsubscript{i} progressively increased at an average rate of 0.04 nM/s. As controls, but also to gain information on their actions on ICaS, the pharmacological agents used in this work were first tested for their basal effects on [Ca\textsuperscript{2+}]\textsubscript{i} in round spermatids (S2 Fig). The inhibitor 2-APB (an inhibitor of IP3-sensitive ICaS channels), ERK inhibitory peptide II (Inhibitor peptide I fused to HIV-TAT), KN62 (an inhibitor of CAMK2) and SCH 202676 (a sulfhydryl-reactive compound inhibiting G protein binding to GPRs) induced significant rises in [Ca\textsuperscript{2+}]\textsubscript{i} in these cells. Conversely, TFP (calmodulin inhibitor, but also described as a ryanodine-sensitive channel agonist, [57]) and ArisA (inhibitor of PLA2) were able to significantly decrease the basal rate of [Ca\textsuperscript{2+}]\textsubscript{i} changes in round spermatids. Since the cells are in a media with approximately 5 nM external Ca\textsuperscript{2+}, any increase in [Ca\textsuperscript{2+}]\textsubscript{i} can be interpreted as Ca\textsuperscript{2+} release from ICaS. Decreases in the basal rate of [Ca\textsuperscript{2+}]\textsubscript{i} changes can be interpreted as a net decrease in Ca\textsuperscript{2+} release from ICaS, or activation of plasma membrane associated Ca\textsuperscript{2+} efflux.

Fig 2. GPR120 immunohistochemistry and immunofluorescence. Representative immunohistochemistry and immunofluorescence images of 60 day old rat testes slices cut in a cryostat using an anti-rat GPR120 rabbit antibody (4 μg/mL) (A, C and D). The secondary antibody and stain developing system was a donkey anti-rabbit antibody coupled to an HRP/DAB system (A and B). A control using rabbit pre-immune serum instead of primary antibody is shown in (B). White arrows point toward spermatids. The asterisk (*) and the black arrow head indicate seminiferous tubule lumen and interstitium, respectively. The bar shown in Figures A, B and C represents 100 μm. C. Confocal images obtained using as primary antibodies an anti-rat GPR120 rabbit antibody (8 μg/mL) and an anti-PCNA mouse antibody. An anti-rabbit IgG antibody conjugated to Alexa Fluor 488 and anti-mouse IgG antibody conjugated to DyLight 549 were used as secondary antibodies. D. Amplified image of the square shown in C.

doi:10.1371/journal.pone.0172128.g002
Pharmacological evidence that GPR/G proteins are involved in the AA-induced changes in \([\text{Ca}^{2+}]_i\) in round spermatids

In order to explore the possible involvement of G protein-associated pathways activated by AA, we tested the effects of the following compounds: 1) SP 4–11, a Substance P-like hydrophobic peptide claimed to compete with its receptor binding to G proteins used here as a control peptide [23]; 2) mastoparan, a bee-venom derived cationic peptide described to stimulate GTP exchange and activation of G protein but to compete in general for G protein receptor binding [20]; and 3) SCH202676, a sulfhydryl-reactive compound shown to inhibit agonist and antagonist binding to G-protein-coupled receptors [22]. As shown in Fig 3, mastoparan at concentrations of 5 and 15 \(\mu\)M, and SCH202676 at 1 \(\mu\)M were able to induce significant decreases in the AA-induced (4 \(\mu\)M) \([\text{Ca}^{2+}]_i\) increase in round spermatids. Thus, our data are consistent with involvement of G proteins in the signalling associated to the AA-induced \([\text{Ca}^{2+}]_i\) changes in round spermatids. In rat round spermatids, the commercially available inhibitor for GPR120 (AH7614, Tocris BioScience) induced by itself an increase in \([\text{Ca}^{2+}]_i\) in the absence of AA, discarding its use as an inhibitor of the AA-induced \([\text{Ca}^{2+}]_i\) increases.
shown in these cells. No further testing on the mechanisms of AH7614-induced changes in round spermatids \([\text{Ca}^{2+}]_i\) was performed in this work.

**Pharmacological evidence for signalling pathways involved in the AA-induced changes in \([\text{Ca}^{2+}]_i\) in round spermatids**

In order to explore the signalling pathways associated to AA-induced \(\text{Ca}^{2+}\) release from ICaS, we utilized ERK inhibitory peptide I, \([26]\) and ERK inhibitory peptide II (Inhibitor peptide I fused to HIV-TAT), Akt Inhibitors 4 \([25,58]\) and 5 \([25]\) and wortmannin, an inhibitor of PI3K \([27]\) (see Fig 4 and S3A Fig). Neither wortmannin nor Akt inhibitors 4 or 5 produced a significant change in the AA-induced \(\text{Ca}^{2+}\) release from ICaS. Instead, ERK inhibitory peptide I induced a significant decrease in the AA-induced \(\text{Ca}^{2+}\) release from ICaS. ERK inhibitory peptide II resulted in a large variance and did not produce a statistically significant effect. Since ERK inhibitory peptide II is expected to bind to membranes, it is likely that its free concentration could be comparatively less than inhibitor peptide 1 and also it can be expected to induce membrane structure perturbations in these cells. Regardless, our data suggest that ERK could be involved in the signalling and activating pathways associated with the AA effect on \([\text{Ca}^{2+}]_i\) in these cells.

Since AA-induced \([\text{Ca}^{2+}]_i\) changes could trigger activation of \(\text{Ca}^{2+}\) signalling in round spermatids, we explored pharmacologically whether calmodulin, CAMK, PKC or PKA could be involved in the AA effect of ICaS release in these cells. For that purpose, we used trifluoperazine (TFP, a non-specific CaM inhibitor; \([57]\)), calmidazolium (CMDZ, a CAM inhibitor; e.g., \([29]\)), KN-62 an inhibitor of CAMKII \([33]\), bisindolylmaleimide (BIM) as a general inhibitor of PKC \([28]\) and forskolin as an activator of adenylyl cyclase (AC) (FSK; \([59]\); see also \([30]\) for non-specific actions of FSK). The data (S3B Fig) show that the AA-induced \(\text{Ca}^{2+}\) release in round spermatids was significantly inhibited by trifluoperazine (a nonspecific CaM inhibitor, also described as a ryanodine-sensitive channel agonist, \([57]\)) but not by calmidazolium, a drug also known to be an inhibitor of CaM (both drugs appear to have CaM-independent effects on TRPV1 channels; see \([60]\)). Hence, the results of TFP cannot be interpreted unequivocally as a result of CaM inhibition. KN62 and BIM did not produce significant changes in the AA-induced \(\text{Ca}^{2+}\) release from ICaS, strongly suggesting that CaM, CaMK or PKC are not part of the pathways activated by AA in round spermatids. Forskolin, an activator of adenyllyl cyclase and hence of PKA, did not significantly affect the AA-induced release of \(\text{Ca}^{2+}\) from ICaS, suggesting that extra generation of cAMP and, likely, further PKA activation did not affect the pathways that AA triggers in these cells. However, H89, an inhibitor of PKA and other kinases \([32]\) significantly increased the potency of AA as an inducer of \(\text{Ca}^{2+}\) release from ICaS. A similar outcome was observed for PT1, an AMPK activator.

Since the mentioned pharmacology suggested the involvement of protein phosphorylation in the AA-induced release of \(\text{Ca}^{2+}\) from ICaS in round spermatids, we used okadaic acid (OA, e.g., \([39]\)), cantharidin (Canth, \([37]\)) and cyclosporine A (CspA) as inhibitors of protein phosphatases and the \(\text{Ca}^{2+}\)-CaM-dependent protein phosphatase calcineurin (e.g., \([38]\)). S3C Fig shows that OA, Canth and CspA did not produce a significant effect on the ability of AA to release \(\text{Ca}^{2+}\) from ICaS.

One possible mechanism by which AA can induce the release of \(\text{Ca}^{2+}\) from ICaS could be via the activation of PLC and the generation of IP3. To test this hypothesis we used as pharmacological agents, U73122, an inhibitor of PLC (2 \(\mu\)M; e.g., \([61]\)) and U73334, a described inactive analogue of U73122 (2 \(\mu\)M; \([42]\)). Neither compound produced a significant effect on AA-induced \(\text{Ca}^{2+}\) release from ICaS in round spermatids (see S3D Fig). Aristolochic acid, an inhibitor of PLA2 (50 \(\mu\)M, e.g., \([40]\)) significantly decreased the AA-induced changes in...
[Ca\(^{2+}\)]_i in round spermatids. Thus, the effects of AA could involve a positive feedback loop, releasing AA or other PUFAs in round spermatids via the activation of PLA2.

**Pharmacological evidence of different intracellular Ca\(^{2+}\) store compartments involved in the AA-induced increase in [Ca\(^{2+}\)]_i in round spermatids**

As shown by Paillamanque et al. [11] and the present data, AA induced the release of Ca\(^{2+}\) form ICaS. Currently, ICaS are thought to comprise essentially three intracellular compartments: endoplasmic reticulum/nuclear envelope (including their own internal binding proteins; e.g., [62,63]), the mitochondria [64] and the acidic organelles-associated ICaS (e.g., [52]). As previously described, round spermatids have ICaS that can be depleted by treatment with thapsigargin (TSG) or cyclopiazonic acid (CPA), which are both inhibitors of the SERCA type Ca\(^{2+}\)-ATPase [65–67]. Here, in order to test the type of ICaS channels that AA was activating in round spermatids we utilized a pharmacological approach using inhibitors of IP3-activated channels (2APB, [48]); of cADPribose-activated channel (RyR) (ryanodine and dantrolene, [45]); of mitochondrial Ca\(^{2+}\) uptake (Ru360, [47]) and of NAADP-activated channels (NED19, [46]). Of the mentioned inhibitors (Fig 5), ryanodine (1 h preincubation) produced approximately 60% inhibition of the AA-induced initial rate of Ca\(^{2+}\) release from ICaS. NED 19 (5 μM), the inhibitor of two-pore Ca\(^{2+}\) channels from acidic ICaS, produced an average of 50% inhibition of the AA-induced initial rate of Ca\(^{2+}\) release from ICaS.
Caffeine in a wide concentration range tested (0.1–1 mM) did not have an effect on basal 
$[\text{Ca}^{2+}]_i$ (see also, [67]) or on the AA-induced initial rate of $\text{Ca}^{2+}$ release from ICaS.

NAADP-activated $\text{Ca}^{2+}$ release from ICaS in round spermatids

Since NED19 induced significant inhibition of the AA-induced $\text{Ca}^{2+}$ release from ICaS, we tested for the existence of the described NAADP-dependent stores in round spermatids. For that purpose we used a permeable analogue of NAADP [56] that has been recently utilized to demonstrate the presence and physiological role of this $\text{Ca}^{2+}$ releasing mechanism in human sperm [68]. As shown in Fig 6, NAADP-AM was able to increase $[\text{Ca}^{2+}]_i$ in round spermatids in a dose-dependent fashion with a $K_{0.5}$ and $V_{max}$ of $2.23\pm0.75 \mu M$ and $0.23\pm0.02 \text{nM/s}$, respectively. Since the acethoxymethyl group in NAADP-AM is cleaved by intracellular esterases, the intracellular NAADP concentration is expected to be higher than the external concentration. As a reference, we show in the same graph the AA (4 $\mu M$) induced rate of $[\text{Ca}^{2+}]_i$
changes. At 4 μM, NAADP-AM was able to induce an ICaS Ca\textsuperscript{2+} release rate approximately 35% of that induced by AA at the same concentration. Pre-incubation of the cells for 30 min with 25 μM NED19, an inhibitor of NAADP activated intracellular Ca\textsuperscript{2+} channels, produced on average a 95% inhibition of the NAADP-AM (1 μM)-induced Ca\textsuperscript{2+} release from ICaS in round spermatids.

Discussion

Since the 1970’s, important evidence has been collected about the peculiar lipid composition of germinal cells and SCs in the testes, specifically their high content of UFAs [21,69–71]. However, the physiological significance of UFAs in the male germinal epithelium has remained unknown. In a previous work [11] we demonstrated that free UFAs can release Ca\textsuperscript{2+} from intracellular Ca\textsuperscript{2+} stores (ICaS) in pachytene spermatocytes and round spermatids. The results presented in this work strongly suggest that arachidonic acid (AA), a PUFA that can be released to the external media by SCs [4], can trigger a GPR120 (FFAR4)-like activation response in round spermatids. Thus, the dose-response curve for the AA effect on [Ca\textsuperscript{2+}]i had a similar K\textsubscript{0.5} to grifolic acid, a GPR120 agonist. However, this GPR120 agonist showed a stronger ability to induce intracellular Ca\textsuperscript{2+} release compared to AA. An antibody against rat C-terminal domain of GPR120 resulted in a marked labelling of interstitial cells and spermatid cells close to the lumen of the seminiferous tubules, which is consistent with a likely GPR120-mediated effect of AA on [Ca\textsuperscript{2+}]i in round spermatids as shown here and in [11].

The effect of AA on [Ca\textsuperscript{2+}]i was sensitive to G protein-receptor interaction, and appeared to involve ERK activation, and PLA2 activation. The possible participation of PLA2 and ERK
and associated mechanisms of activation in the AA-induced release of Ca\(^{2+}\) from ICaS were not further explored in this work. Similarly, the mechanisms associated to the potentiation by activation of AMPK or inhibition of PKA on the effects of AA on ICaS release in round spermatids were not explored in this work. The effects of AA on ICaS release and the association with ERK in round spermatids are similar to those elicited by ω3 and ω6 PUFAs in Caco-2 cells, which express GPR120 but not GPR40 (FFAR1, another GPR for free medium- and large-chain fatty acids) [72]. In these cells, AA, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), all used at 100–200 μM (i.e., at 12–25 times higher concentration that in our work) increased [Ca\(^{2+}\)]\(_i\) and activated ERK1/2 in Caco-2 cells. Similarly, in HEK cells expressing GPR120 [73], oleic acid and a synthetic GPR120 agonist induced increments in [Ca\(^{2+}\)]\(_i\) with \(K_{0.5}\) values close to those found for grifolic acid and AA in our work. As for the possible involvement of a PLA2 in the AA-induced release of Ca\(^{2+}\) from intracellular stores suggested by our results, no literature has linked AA-Ca\(^{2+}\) and PLA2 in spermatogenic cells to our knowledge. However, Ca\(^{2+}\)-dependent and Ca\(^{2+}\)-independent PLA2 have been described in

---

**Fig 7. Summary diagram.** Diagram showing the likely activation mechanisms of PUFA release from Sertoli cells (SC) and their mechanisms of action on spermatogenic cell intracellular Ca\(^{2+}\) stores.

doi:10.1371/journal.pone.0172128.g007
the testes and specifically in spermatogenic cells [74–76] and their appearance during development is correlated to the initiation of meiosis in germ cells [75].

As reported by Treviño et al. [67], spermatogenic cells express IP3-sensitive and cADPR-sensitive intracellular Ca2+ channels. In the present study, we demonstrated functionally that round spermatids also possess NAADP-sensitive intracellular Ca2+ channels in ICaS.

Our results strongly suggest that cADPR- and NAADP-sensitive intracellular Ca2+ channels are involved in the AA-induced Ca2+ release from ICaS in round spermatids, which correlates well with the molecular infrastructure that these cells possess.

Fig 7 summarizes the working model of AA-activated pathways in spermatogenic cells, the associated cell-cell interactions in the testes and their likely endocrine regulation. Thus, free fatty acid lipid signalling in the seminiferous tubules is proposed as an important mechanism for cell-cell interactions in the seminiferous epithelium associated to the regulation of spermatogenesis in the testes.

Supporting information

S1 Fig. Kinetics of grifolic acid-induced [Ca2+]i changes. Kinetics of grifolic acid-induced [Ca2+]i increase in round spermatids. At the times indicated by arrows, grifolic acid or arachidonic acid (4 μM) were added to round spermatids previously loaded with fura-2 and incubated in KH-lactate-EGTA media without added Ca2+ at 33˚C.

(TIF)

S2 Fig. Effects of pharmacological agents on basal [Ca2+]i. Basal effects of different pharmacological molecules used in this work on the [Ca2+]i changes in round spermatids. Each bar and error bar represents the average and standard deviation of data obtained for at least 3 cell preparations (N = 3).

(TIF)

S3 Fig. Effects of signalling pathways modulators on AA-induced increase in [Ca2+]i. A. Effects of ERK, Akt and PI3K inhibitors on the AA-induced (4 μM) release of Ca2+ from intracellular stores. ERK inhibitor I (10 μM), ERK inhibitor II (5 μM), PI3K inhibitor: wortmannin (1 μM), Akt inhibitor IV (1 μM) and Akt Inhibitor V (1 μM) were added to the cells in suspension and incubated for 5 min at 33˚C before AA addition. Significance: *p<0.01. N = 3. B. Effects of CaM, PKC, PKA, AMPK inhibitors or activators on the AA-induced (4 μM) release of Ca2+ from intracellular stores. CaM inhibitors: trifluoperazine (TFP, 20 μM), calmidazolium (Cmdz, 2 μM), KN-62 (5 μM). PKC inhibitor: bisindoylmaleimide (BIM, 2 μM). AC activator: forskolin (FSK, 5 μM). AMPK activator: PT1 (2 μM). PKA inhibitor: H89 (2 μM) were added to the cells in suspension and incubated for 5 min at 33˚C before AA addition. Significance: *p<0.05. N = 3. C. Effects of protein phosphatase (PPase) inhibitors on the AA-induced (4 μM) release of Ca2+ from intracellular stores. Okadaic acid (OA, 0.2 μM), cantharidin (Canth, 5 μM) and cyclosporine A (CspA, 5 μM) were added to the cells in suspension and incubated for 5 min at 33˚C before AA addition. N = 3. D. Effects of phospholipases inhibitors on the AA-induced (4 μM) release of Ca2+ from intracellular stores. Arachidonic acid (ArA, inhibitor of PLA2, 50 μM). U73122 (inhibitor of PLC, 2 μM) and U73343 (inactive analogue of U73122, 2 μM) were added to the cells in suspension and incubated for 5 min at 33˚C before AA addition. Significance: *p<0.05. N = 3. Each bar and error bar in S3 Fig (A, B, C and D) represents the average and standard deviation of data obtained for at least 3 cell preparations (N = 3).

(TIF)
Author Contributions

Conceptualization: JGR JP NO EMC CLT.
Data curation: JP EMC CS JGR NO CLT.
Formal analysis: JGR JP EMC NO CLT CS.
Funding acquisition: JGR CLT NO FN.
Investigation: JP EMC CS AS-T NO FN JGR.
Methodology: JGR NO CLT JP CS EMC FN.
Project administration: JGR CLT NO JP EMC.
Resources: JGR CLT NO FN.
Supervision: JGR NO CLT FN.
Validation: JGR JP EMC NO AS-T FN CLT CS.
Visualization: JP EMC JGR CLT NO CS FN.
Writing – original draft: JP EMC JGR NO CLT.
Writing – review & editing: JGR JP EMC NO AS-T CLT CS FN.

References

1. Sofikitis N, Giotitsas N, Tsounapi P, Baltogiannis D, Giannakis D, Pardalidis N (2008) Hormonal regulation of spermatogenesis and spermiogenesis. J Steroid Biochem Mol Biol 109: 323–330. doi: 10.1016/j.jsbmb.2008.03.004 PMID: 18400489
2. Jegou B (1993) The Sertoli-germ cell communication network in mammals. Int Rev Cytol 147: 25–96. PMID: 8225836
3. Huleihel M, Abuelhija M, Lunenfeld E (2007) In vitro culture of testicular germ cells: regulatory factors and limitations. Growth Factors 25: 236–252. doi: 10.1080/08977190701783400 PMID: 18092232
4. Jannini EA, Ulisse S, Cecconi S, Cironi L, Colonna R, D’Armiento M, et al. (1994) Follicle-stimulating hormone-induced phospholipase A2 activity and eicosanoid generation in rat Sertoli cells. Biol Reprod 51: 140–145. PMID: 7918869
5. Lee J, Richburg JH, Younkin SC, Boekelheide K (1997) The Fas system is a key regulator of germ cell apoptosis in the testis. Endocrinology 138: 2081–2088. doi: 10.1210/endo.138.5.5110 PMID: 9112408
6. Lizama C, Alfaro I, Reyes JG, Moreno RD (2007) Up-regulation of CD95 (Apoptosis) is associated with spermatocyte apoptosis during the first round of spermatogenesis in the rat. Endocrinology 12: 499–512. doi: 10.1007/s10495-006-0012-1 PMID: 17195944
7. Ulisse S, Cinque B, Silvano G, Rucci N, Biordi L, Cifone MG, et al. (2000) Erk-dependent cytosolic phospholipase A2 activity is induced by CD95 ligand cross-linking in the mouse derived Sertoli cell line TM4 and is required to trigger apoptosis in CD95 bearing cells. Cell Death Differ 7: 916–924. doi: 10.1038/sj.cdd.4400716 PMID: 11279537
8. Meroni SB, Riera MF, Pellizzari EH, Schteingart HF, Cigorraga SB (2003) Possible role of arachidonic acid in the regulation of lactate production in rat Sertoli cells. Int J Androl 26: 310–317. PMID: 14511220
9. MacDonald ML, Rogers QR, Morris JG, Cupps PT (1984) Effects of linoleate and arachidonate deficiencies on reproduction and spermatogenesis in the cat. J Nutr 114: 719–726. PMID: 6716173
10. Bao S, Miller DJ, Ma Z, Wohltmann M, Eng G, Ramanadham S, et al. (2004) Male mice that do not express group VIA phospholipase A2 produce spermatozoa with impaired motility and have greatly reduced fertility. J Biol Chem 279: 38194–38200. doi: 10.1074/jbc.M406489200 PMID: 15252026
11. Paillamanque J, Madrid C, Carmona EM, Osnes N, Moreno RD, Oresti GM, et al. (2016) Effects of Fatty Acids on Intracellular [Ca²⁺], Mitochondrial Uncoupling and Apoptosis in Rat Pachytene Spermatocytes and Round Spermatids. PLoS One 11: e0158518. doi: 10.1371/journal.pone.0158518 PMID: 27420262
12. Romrell LJ, Bellve AR, Fawcett DW (1976) Separation of mouse spermatogenic cells by sedimentation velocity. A morphological characterization. Dev Biol 49: 119–131. PMID: 176074

13. Reyes JG, Diaz A, Osses N, Opazo C, Benos DJ (1997) On stage single cell identification of rat spermatogenic cells. Biol Cell 89: 53–66. PMID: 9297783

14. Shimpuka B, Hudson BD, Hovgaard CK, Milligan G, Ulven T (2012) Discovery of a potent and selective GPR120 agonist. J Med Chem 55: 4511–4515. doi: 10.1021/jm300215x PMID: 22519963

15. Christiansen E, Urban C, Grundmann M, Due-Hansen ME, Hagesaether E, Schmidt J, et al. (2011) Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties. J Med Chem 54: 6691–6703. doi: 10.1021/jm2005699 PMID: 21854074

16. Hara T, Hirasaawa A, Sun Q, Sadakane K, Itsubo C, Iga T, et al. (2009) Novel selective ligands for free fatty acid receptors GPR120 and GPR40. Naunyn Schmiedebergs Arch Pharmacol 380: 247–255. doi: 10.1007/s00210-009-0425-9 PMID: 19471906

17. Briscoe CP, Peat AJ, McKeown SC, Corbett DF, Goetz AS, Littleton TR, et al. (2006) Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol 148: 619–628. doi: 10.1038/sj.bjp.0706770 PMID: 16702987

18. Moussi M, Bueb JL, Bronner C, Routou B, Landry Y (1990) G protein activation: a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides. Trends Pharmacol Sci 11: 358–362. PMID: 2122563

19. Raynor RL, Zheng B, Kuo JF (1991) Membrane interactions of amphiphilic polypeptides mastoparan, melittin, polymyxin B, and cardiotoxin. Differential inhibition of protein kinase C, Ca2+/calmodulin-dependent protein kinase II and synaptosomal membrane Na,K-ATPase, and Na+ pump and differentiation of HL60 cells. J Biol Chem 266: 2753–2758. PMID: 1847132

20. Higashijima T, Burnier J, Ross EM (1990) Regulation of Gi and Go by mastoparan, related amphiphilic peptides, and hydrophobic amines. Mechanism and structural determinants of activity. J Biol Chem 265: 14176–14186. PMID: 2117607

21. Gao ZG, Gross AS, Jacobson KA (2004) Effects of the allosteric modulator SCH-202676 on adenosine and P2Y receptors. Life Sci 74: 3173–3180. doi: 10.1016/j.lfs.2003.11.014 PMID: 15081581

22. Lewandowicz AM, Vepsalainen J, Laitinen JT (2006) The ‘allosteric modulator’ SCH-202676 disrupts G protein-coupled receptor function via sulphhydryl-sensitive mechanisms. Br J Pharmacol 147: 422–429. doi: 10.1038/sj.bjp.0706624 PMID: 16402041

23. Mukai H, Munekata E, Higashijima T (1992) G protein antagonists. A novel hydrophobic peptide competes with receptor for G protein binding. J Biol Chem 267: 16237–16243. PMID: 1379592

24. Regoli D, Escher E, Mizrahi J (1984) Substance P—structure-activity studies and the development of antagonists. Pharmacology 28: 301–320. PMID: 6203130

25. Sun RQ, Tu YJ, Yan JY, Willis WD (2006) Activation of protein kinase B/Akt signaling pathway contributes to mechanical hypersensitivity induced by capsaicin. Pain 120: 86–96. doi: 10.1016/j.pain.2005.10.017 PMID: 16360265

26. Rasola A, Sciavicovelli M, Chiara F, Pantic B, Brusilow WS, Bernardi P (2010) Activation of mitochondrial ERK protects cancer cells from death through inhibition of the permeability transition. Proc Natl Acad Sci U S A 107: 726–731. doi: 10.1073/pnas.0912742107 PMID: 20080742

27. Powis G, Bonjouklian R, Berggren MM, Gallegos A, Abraham R, Ashendel C, et al. (1994) Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res 54: 2419–2423. PMID: 8162590

28. Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perr et T, Ajakane M, et al. (1991) The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem 266: 15771–15781. PMID: 1874734

29. Lamers JM, Stinis JT (1983) Inhibition of Ca2+-dependent protein kinase and Ca2+/Mg2+-ATPase in cardiac sarcolemma by the anti-calm modulin drug calmidazolium. Cell Calcium 4: 281–294. PMID: 6139171

30. Laurens A, Sutkowski EM, Seamon KB (1989) Forskolin: a specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action? Trends Pharmacol Sci 10: 442–447. doi: 10.1016/S0165-6147(89)80008-2 PMID: 2692256

31. Chijiwa T, Mishima A, Hagiwara M, Sano M, Hayashi K, Inoue T, et al. (1990) Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isouquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem 265: 5267–5272. PMID: 2156866
32. Lochner A, Moolman JA (2006) The many faces of H89: a review. Cardiovasc Drug Rev 24: 261–274. doi: 10.1111/j.1527-3466.2006.00261.x PMID: 17214602

33. Tohda M, Nakamura J, Hidaka H, Nomura Y (1991) Inhibitory effects of KN-62, a specific inhibitor of Ca/calmodulin-dependent protein kinase II, on serotonin-evoked C1-current and 36-C1-efflux in Xenopus oocytes. Neurosci Lett 129: 47–50. PMID: 1656340

34. Zorn JA, Wells JA (2010) Turning enzymes ON with small molecules. Nat Chem Biol 6: 179–188. doi: 10.1038/nchembio.318 PMID: 20154666

35. Pang T, Zhang ZS, Gu M, Qiu BY, Yu LF, Cao PR, et al. (2008) Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells. J Biol Chem 283: 16051–16060. doi: 10.1074/jbc.M71114200 PMID: 18321858

36. Levin RM, Weiss B (1980) Inhibition by trifluoperazine of calmodulin-induced activation of ATPase activity of rat erythrocyte. Neuropharmacology 19: 169–174. PMID: 6447400

37. Honkanen RE (1993) Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Lett 330: 283–286. PMID: 8397101

38. Guerini D (1997) Calcineurin: not just a simple protein phosphatase. Biochem Biophys Res Commun 235: 271–275. doi: 10.1006/bbrc.1997.6802 PMID: 9199180

39. Haystead TA, Sim AT, Carling D, Honnor RC, Tsukitani Y, Cohen P, et al. (1989) Effects of the tumour promoter okadaic acid on intracellular protein phosphorylation and metabolism. Nature 337: 78–81. doi: 10.1038/337078a0 PMID: 2562908

40. Vishwanath BS, Fawzy AA, Franson RC (1988) Edema-inducing activity of phospholipase A2 purified from human synovial fluid and inhibition by aristolochic acid. Inflammation 12: 549–561. PMID: 3220517

41. Rosenthal MD, Vishwanath BS, Franson RC (1989) Effects of aristolochic acid on phospholipase A2 activity and arachidonate metabolism of human neutrophils. Biochim Biophys Acta 1001: 1–8. PMID: 2536283

42. Jin W, Lo TM, Loh HH, Thayer SA (1994) U73122 inhibits phospholipase C-dependent calcium mobilization in neuronal cells. Brain Res 642: 237–243. PMID: 8032888

43. Smith RJ, Justen JM, McNab AR, Rosenbloom CL, McNab AR, Detmers PA, et al. (1996) U-73122: a potent inhibitor of human polymorphonuclear neutrophil adhesion on biological surfaces and adhesion-related effector functions. J Pharmacol Exp Ther 278: 320–329. PMID: 8764386

44. Kong H, Jones PP, Koop A, Zhang L, Duff HJ, Chen SR (2008) Caffeine induces Ca2+ release by reducing the threshold for luminal Ca2+ activation of the ryanodine receptor. Biochem J 414: 441–452. doi: 10.1042/BJ20080489 PMID: 18518861

45. Zhao F, Li P, Chen SR, Louis CF, Fruen BR (2001) Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity. J Biol Chem 276: 13810–13816. doi: 10.1074/jbc.M006104200 PMID: 11278995

46. Naylor E, Arredouani A, Vasudevan SR, Lewis AM, Parkesh R, Mizote A, et al. (2009) Identification of a chemical probe for NAADP by virtual screening. Nat Chem Biol 5: 220–226. doi: 10.1038/ncembio.2011.130 PMID: 19234453

47. Mathur MA, Zhou Z, Knight S, Ahmed S, Choi KM, Krause-Bauer J, et al. (1998) Oxygen-bridged dinuclear ruthenium amine complex specifically inhibits Ca2+ uptake into mitochondria in vitro and in situ in single cardiac myocytes. J Biol Chem 273: 10223–10231. PMID: 9553073

48. Maruyama T, Kanaji T, Nakade S, Kanno T, Mikoshi K (1997) 2APB, 2-amino ethoxydiph enyl borate, a membrane-penetrable modulator of the ryanodine receptor. Biochem J 320: 57–62. doi: 10.1042/BJ19970331 PMID: 9348073

49. Sutko JL, Airey JA, Welch W, Ruest L (1997) The pharmacology of ryanodine and related compounds. Pharmacol Rev 49: 53–98. PMID: 9085309

50. Adasme T, Paula-Lima A, Hidalgo C (2015) Inhibitory ryanodine prevents ryanodine receptor-mediated Ca2+ release in partially purified endoplasmic reticulum Ca2+ content in primary hippocampal neurons. Biochem Biophys Res Commun 458: 57–62. doi: 10.1016/j.bbrc.2015.01.065 PMID: 25629393

51. Meissner G (1986) Ryanodine activation and inhibition of the Ca2+ release channel of sarcoplasmic reticulum. J Biol Chem 261: 6300–6306. PMID: 2422165

52. Patel S, Ramakrishnan L, Rahman T, Hamdoun A, Marchant JS, Taylor CW, et al. (2011) The endolysosomal system as a NAADP-sensitive acidic Ca2+-store: role for the two-pore channels. Cell Calcium 50: 157–167. doi: 10.1016/j.ceca.2011.03.011 PMID: 21529939

53. Grynkiewicz G, Poenie M, Tsien RY (1985) A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 260: 3440–3450. PMID: 3838314
54. Latendresse JR, Warbritton AR, Jonassen H, Creasy DM (2002) Fixation of testes and eyes using a modified Davidson’s fluid: comparison with Bouin’s fluid and conventional Davidson’s fluid. Toxicol Pathol 30: 524–533. PMID: 12187944

55. Abràmoff MD, Magalhães PJ, Ram SJ (2004) Image Processing with ImageJ. Biophotonics International 11: 36–43.

56. Parkesh R, Lewis AM, Aley PK, Arredouani A, Rossi S, Tavares R, et al. (2008) Cell-permeant NAADP: a novel chemical tool enabling the study of Ca2+ signalling in intact cells. Cell Calcium 43: 531–538. doi: 10.1016/j.ceca.2007.09.006 PMID: 18308090

57. Qin J, Zima AV, Porta M, Blatter LA, Fil M (2009) Trifluoperazine: a ryanodine receptor agonist. Pflugers Arch 458: 643–651. doi: 10.1007/s00424-009-0658-y PMID: 19277699

58. Thamilselvan V, Craig DH, Basson MD (2007) FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway. FASEB J 21: 1730–1741. doi: 10.1096/fj.06-6545com PMID: 17317726

59. Awad JA, Johnson RA, Jakobs KH, Schultz G (1983) Interactions of forskolin and adenylate cyclase. Effects on substrate kinetics and protection against inactivation by heat and N-ethylmaleimide. J Biol Chem 258: 2960–2965. PMID: 6681815

60. Olah Z, Josvay K, Pecze L, Letoha T, Babai N, Budai D, et al. (2007) Anti-calmodulins and tricyclic adjuvants in pain therapy block the TRPV1 channel. PLoS One 2: e545. doi: 10.1371/journal.pone.0000545 PMID: 17579717

61. Bleasdale JE, Bundy GL, Bunting S, Fitzpatrick FA, Huff RM, Sun FF, et al. (1989) Inhibition of phospholipase C dependent processes by U-73,122. Adv Prostaglandin Thromboxane Leukot Res 19: 590–593. PMID: 2526542

62. Pozzan T, Rizzuto R, Volpe P, Meldolesi J (1994) Molecular and cellular physiology of intracellular calcium stores. Physiol Rev 74: 595–636. PMID: 8036248

63. Mauger JP (2012) Role of the nuclear envelope in calcium signalling. Biol Cell 104: 70–83. doi: 10.1111/boc.201100113 PMID: 22188206

64. Pozzan T, Rizzuto R (2000) The renaissance of mitochondrial calcium transport. Eur J Biochem 267: 5269–5273. PMID: 10951183

65. Herrera E, Salas K, Lagos N, Benos DJ, Reyes JG (2000) Energy metabolism and its linkage to intracellular Ca2+ and pH regulation in rat spermatogenic cells. Biol Cell 92: 429–440. PMID: 11132704

66. Berrios J, Osses N, Opazo C, Arenas G, Mercado L, Benos DJ, et al. (1998) Intracellular Ca2+ homeostasis in rat round spermatids. Biol Cell 90: 391–398. PMID: 9835013

67. Trevino CL, Santi CM, Beltran C, Hernandez-Cruz A, Darszon A, Lomeli H (1998) Localization of inositol trisphosphate and ryanodine receptors during mouse spermatogenesis: possible functional implications. Zygote 6: 159–172. PMID: 9770782

68. Sanchez-Tusie AA, Vasudevavan SR, Churchill GC, Nishigaki T, Trevino CL (2014) Characterization of NAADP-mediated calcium signaling in human spermatozoa. Biochem Biophys Res Commun 443: 531–536. doi: 10.1016/j.bbrc.2013.12.011 PMID: 24326068

69. Oresti GM, Reyes JG, Luqueze JM, Osses N, Furland NE, Aveldano MI (2010) Differentiation-related changes in lipid classes with long-chain and very long-chain polyenoic fatty acids in rat spermatogenic cells. J Lipid Res 51: 2909–2921. doi: 10.1194/jlr.M006429 PMID: 20610732

70. Beckman JK, Coniglio JG (1979) A comparative study of the lipid composition of isolated rat Sertoli and germinal cells. Lipids 14: 262–267. PMID: 4495068

71. Grogan WM, Farnham WF, Szopiak BA (1981) Long chain polyenoic acid levels in viably sorted, highly enriched mouse testis cells. Lipids 16: 401–410. PMID: 7266265

72. Mobraten K, Haug TM, Kleiveland CR, Lea T (2013) Omega-3 and omega-6 PUFAs induce the same GPR120-mediated signalling events, but with different kinetics and intensity in Caco-2 cells. Lipids Health Dis 12: 101. doi: 10.1186/1476-511X-12-101 PMID: 23849180

73. Watson SJ, Brown AJ, Holliday ND (2012) Differential signaling by splice variants of the human free fatty acid receptor GPR120. Mol Pharmacol 81: 631–642. doi: 10.1124/mol.111.077388 PMID: 22282525

74. Masuda M, Murakami M, Matsumoto S, Eguchi N, Urade Y, Lambeau G, et al. (2004) Localization of various secretory phospholipase A2 enzymes in male reproductive organs. Biochim Biophys Acta 1686: 61–76. doi: 10.1016/j.bbalip.2004.08.017 PMID: 15522823

75. Ma Z, Turk J (2001) The molecular biology of the group VIA Ca2+-independent phospholipase A2. Prog Nucleic Acid Res Mol Biol 67: 1–33. PMID: 11525380

76. Chen J, Engle SJ, Seilhammer JJ, Tischfeld JA (1994) Cloning and characterization of novel rat and mouse low molecular weight Ca(2+)-dependent phospholipase A2s containing 16 cysteines. J Biol Chem 269: 23018–23024. PMID: 8083202